Find new investment opportunities based on Market Sentiment Indicator. Manage watchlist risk with leading indicator of volatility See what influential analysts and investors are saying about stocks in My Watchlist
Most Trending
+3.41%
+15.34%
-2.61%
-8.11%
-1.05%
ATAI
ATAI Life Sciences
$6.10
Strengths
Upgraded on attractively valued
Trading below its fair value
Chart
$5.49 (+11.11%)
$3.31 (+84.29%)
$2.31 (+164.07%)
$1.08 (+464.81%)
ATAI has Extreme Risk Level based on volatility, sector strength, volume, investor confidence, and outlook. Click here to check what is your level of risk
Risks Indicators
Beta greater than 1.0
High volatilty
ATAI overall standing based on key factors, offering insights into analysts perspectives and market expectations.
Hover over the category for more information
Earnings
Earnings
Revenue increase YoY
Below analyst estimate
Rating
Rating
Upgraded on attractively valued
Momentum
Momentum
Has been gaining momentum
Activity
Activity
Future
Future
Trading below its fair value
ATAI Analysts opinion is positive and it remained unchanged from the past 3 months
Analysts perspectives on the stock desirability, trend direction, and growth potential.
ATAI Street view is extremely bullish and have positive views on the near-term outlook
Average key support and resistance price levels.
What is ATAI current stock price?
What are ATAI stock strengths?
What risks are associated with ATAI stock?
When is ATAI next earnings report?
What is ATAI market cap and volume?
What is ATAI's current Stock IQ?
Should I buy ATAI stock right now?
Is ATAI a Strong Buy right now?
What does a 'Strong Buy' rating mean for ATAI?
What does a 'Strong Sell' rating mean for ATAI?
What factors influence ATAI's Stock IQ?
Join over 10,000+ subscribers who value exclusive insights. Stay ahead in the stock market! Enter your email for daily alerts
Stay ahead of the market
Market trends
Investment tips
Market analysis service
Future potential
Informed investment decisions
Investment analysis
IInvestment strategies
In-depth stock analysis
Performance analysis
Stock market insights
Financial trends analysis
Most Trending
+3.41%
+15.34%
-2.61%
-8.11%
-1.05%
ATAI
ATAI Life Sciences
Current Price
$6.10
Stock Insights
Strengths
Upgraded on attractively valued
Trading below its fair value
Chart
$5.49 (+11.11%)
$3.31 (+84.29%)
$2.31 (+164.07%)
$1.08 (+464.81%)
ATAI Analysts Opinion
ATAI Overall standing by considering key factors, reflecting analysts perspectives and market expectations.
Hover over the category for more information
Earnings
Earnings
Revenue increase YoY
Below analyst estimate
Rating
Rating
Upgraded on attractively valued
Momentum
Momentum
Has been gaining momentum
Activity
Activity
Future
Future
Trading below its fair value
ATAI Analysts opinion is positive and it remained unchanged from the past 3 months
Analysts perspectives on the stock desirability, trend direction, and growth potential.
ATAI Street view is extremely bullish and have positive views on the near-term outlook
ATAI has Extreme Risk Level based on volatility, sector strength, volume, investor confidence, and outlook. Click here to check what is your level of risk
Risks Indicators
Beta greater than 1.0
High volatilty
Average key support and resistance price levels.
ATAI Latest Analysis
atai Life Sciences Announces Closing of Public Offering and Full Exercise of Option to Purchase Additional Common Shares. Cash cash equivalents short-term investments and other liquid assets expected to fund operations into 2029 beyond anticipated top-line results from the first Phase 3 clinical trial of BPL-003
Mon Oct 20, 2025
atai Life Sciences (ATAI) Upgraded to Buy: Heres Why. atai Life Sciences (ATAI) might move higher on growing optimism about its earnings prospects which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Mon Oct 20, 2025
Atai Life Sciences Prices Underwritten Offering Of About 23.73 Mln Shares At $5.48/shr . (RTTNews) - atai Life Sciences (ATAI) announced that it has priced its registered underwritten offering of about 23.73 million common shares at a price of $5.48 per share. atai has granted the underwriters a 30-day option to purchase up to an additional 3.56 million common sha
Fri Oct 17, 2025
atai Life Sciences announces proposed public offering of common shares.
Thu Oct 16, 2025
Atai Life Sciences Remains Undervalued Analyst Initiates With Around 125% Stock Upside. Needham on Monday initiated coverage on ATAI) a clinical-stage biopharmaceutical company focused on developing The company’.s lead drug candidate BPL-003 is under development for treatment-resistant depression.Topline results from the eight-week core phase of the Phase 2b study met its primary and all key secondary endpoints and BPL-003 demonstrated rapid robust and .Analyst Needham initiated ...
Mon Oct 13, 2025
Needham Initiates Coverage of Atai Life Sciences N.V. (ATAI) with Buy Recommendation. Fintel reports that on October 13 2025 Needham initiated coverage of Atai Life Sciences N.V. (NasdaqGM:ATAI) with a Buy recommendation. Analyst Price Forecast Suggests 125.71% Upside
Mon Oct 13, 2025
FIND US ON
Unlock the knowledge that 10,000+ subscribers already cherish. Join for exclusive insights and stay ahead in the stock game! Enter your email to receive daily alerts
In-depth stock analysis
Informed investment decisions
Stock market insights
Stock trading tips
ATAI Stock trends
ATAI Stock performance
ATAI Stock analysis
ATAI investment strategies
Disclaimer:
Past performance, whether from actual results or historical strategy tests, does not guarantee future success. The displayed outcomes are based on strategies not previously available to investors and do not depict the returns achieved by any specific investor.
The Readiness Indicators, Sentiment Indicators, and overall score are derived from a model retrospectively applied using historical data. This model relies on assumptions inherent to it, which may or may not be verifiable and carry potential risks, including losses.
Engaging in active trading may not be suitable for individuals with limited resources, minimal investment or trading experience, or a low-risk tolerance. Proceed with caution as your capital is exposed to risks.
Please note that no offer or solicitation to buy or sell securities, securities derivatives of future products of any kind, or any type of trading or invesment advise, recommendation or strategy, is made, given or endorsed by StocksRunner including any of their affiliates ("TS").
This information is provided for illustrative purposes only. You should not rely on any advice and/or information contained in this website and before making any investment decision. we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice.